Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference [Yahoo! Finance]
Anika Therapeutics Inc. (ANIK)
Last anika therapeutics inc. earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anikatherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
operating cash flow), with more than $50M in cash and no debt supporting its balance sheet. Management frames a $3 billion TAM led by $1B opportunities for Hyalofast and Cingal ; Cingal is advancing toward a U.S. NDA (toxicity studies complete, bioequivalence study underway) while Hyalofast's PMA remains in active review after mixed primary/secondary endpoint results. Revenue mix is bifurcated: the OEM channel (Monovisc/Orthovisc via J&J) faces U.S. pricing pressure and may be flat-to-modestly lower in 2026, while the commercial channel is growing in the mid-teens with 2026 guidance of 10–20% growth and company-wide adjusted EBITDA expected at 5–10% of revenue. Interested in Anika Therapeutics Inc.? Here are five stocks we like better. Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company's strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line growth, a di
Show less
Read more
Impact Snapshot
Event Time:
ANIK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIK alerts
High impacting Anika Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ANIK
News
- Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.MarketBeat
- Anika Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Anika Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Anika Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Anika To Present at the Canaccord Genuity 2026 Musculoskeletal ConferenceGlobeNewswire
ANIK
Earnings
- 2/26/26 - Beat
ANIK
Sec Filings
- 3/3/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/3/26 - Form 4
- ANIK's page on the SEC website